257. 肝型糖原病 Disease details / Clinical trials / Drug dev / DR info

Antipyretic
   Ultragenyx Pharmaceutical Inc
      2021   Phase 1/Phase 2   NCT04990388   Canada;France;Italy;Spain;United Kingdom;United States
Carbohydrates intake
   University of British Columbia
      2017   -   NCT03218904   Canada
Cornstarch
   Hospital de Clinicas de Porto Alegre
      2017   -   NCT03871673   Brazil
Dexamethasone
   ULTRAGENYX PHARMACEUTICAL INC.
      2021   Phase 1;Phase 2   EUCTR2021-000903-19-IT   Canada;France;Germany;Italy;Spain;United Kingdom;United States
Empagliflozin
   Children's Memorial Health Institute, Poland
      2021   Phase 2   NCT04930627   Poland
   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
      2019   Phase 2   NCT04138251   Belgium
Ephynal
   Dipartimento di Pediatria
      2006   -   EUCTR2006-005449-12-IT   Italy
Faxe kondi free
   Rigshospitalet, Denmark
      2015   -   NCT02448667   Denmark
Fructose and galactose
   Insel Gruppe AG, University Hospital Bern
      2025   -   NCT06852612   Switzerland
Glucose intake
   University of British Columbia
      2017   -   NCT03218904   Canada
Glycosade
   John Mitchell
      2013   -   NCT02054832   Canada
   University of Manitoba
      2014   -   NCT02176096   Canada
H1 blocker
   Ultragenyx Pharmaceutical Inc
      2021   Phase 1/Phase 2   NCT04990388   Canada;France;Italy;Spain;United Kingdom;United States
H2 blocker
   Ultragenyx Pharmaceutical Inc
      2021   Phase 1/Phase 2   NCT04990388   Canada;France;Italy;Spain;United Kingdom;United States
Mrna CHE codifica L’enzima umano deramificante DEL glicogeno formulato IN UNA nanopaticella lipidica
   ULTRAGENYX PHARMACEUTICAL INC.
      2021   Phase 1;Phase 2   EUCTR2021-000903-19-IT   Canada;France;Germany;Italy;Spain;United Kingdom;United States
Mrna encoding THE human glycogen debranching enzyme formulated IN A lipid nanoparticle delivery
   Ultragenyx Pharmaceutical Inc.
      2022   Phase 1;Phase 2   EUCTR2021-000903-19-FR   Canada;France;Italy;Spain;United Kingdom;United States
      2021   Phase 1;Phase 2   EUCTR2021-000903-19-ES   Canada;France;Germany;Italy;Spain;United Kingdom;United States
Quark
   Dipartimento di Pediatria
      2006   -   EUCTR2006-005449-12-IT   Italy
Ramipril
   Dipartimento di Pediatria
      2006   -   EUCTR2006-005449-12-IT   Italy
Sweet manioc starch
   Hospital de Clinicas de Porto Alegre
      2017   -   NCT03871673   Brazil
Tocopherol
   Dipartimento di Pediatria
      2006   -   EUCTR2006-005449-12-IT   Italy
Triheptanoin
   Areeg El-Gharbawy
      2020   Early Phase 1   NCT03665636   United States
   Baylor Research Institute
      2009   Phase 2   NCT00947960   France;United States
   Copenhagen Neuromuscular Center
      2018   Phase 2   EUCTR2017-004153-17-DK   Denmark
UX007
   Copenhagen Neuromuscular Center
      2018   Phase 2   EUCTR2017-004153-17-DK   Denmark
UX053
   ULTRAGENYX PHARMACEUTICAL INC.
      2021   Phase 1;Phase 2   EUCTR2021-000903-19-IT   Canada;France;Germany;Italy;Spain;United Kingdom;United States
   Ultragenyx Pharmaceutical Inc
      2021   Phase 1/Phase 2   NCT04990388   Canada;France;Italy;Spain;United Kingdom;United States
   Ultragenyx Pharmaceutical Inc.
      2022   Phase 1;Phase 2   EUCTR2021-000903-19-FR   Canada;France;Italy;Spain;United Kingdom;United States
      2021   Phase 1;Phase 2   EUCTR2021-000903-19-ES   Canada;France;Germany;Italy;Spain;United Kingdom;United States
Vegetable OIL
   Baylor Research Institute
      2009   Phase 2   NCT00947960   France;United States